{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.4","value":"66.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"Total Antibody"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.5","value":"21.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"title":"SN-38G"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.6","value":"20.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"}],"units":"Participants"}],"title":"Total SN-38"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.3","value":"15.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"120"}],"units":"Participants"}],"title":"Sacituzumab Govitecan-hziy (SG)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.6","value":"17.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"}],"units":"Participants"}],"title":"Free SN-38"}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"}],"units":"Participants"}],"description":"T1/2 was determined for 5 analytes: total antibody, SN-38 glucuronide, total SN-38, free SN-38, and sacituzumab govitecan-hziy, a derived antibody drug conjugate (ADC) concentration. SN-38 is one of the components of sacituzumab govitecan-hziy. T1/2 is defined as apparent terminal elimination half-life (h); calculated as 0.693/λz. The dose level evaluated for PK analysis was 10 mg/kg.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants included adults with the following tumor types:\n\ncervical cancer, colorectal cancer, endometrial cancer, epithelial ovarian cancer, esophageal cancer, gastric adenocarcinoma, glioblastoma multiforme, head and neck cancers- squamous cell, hepatocellular carcinoma, hormone-refractory prostate cancer, metastatic, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, renal cell cancer, small-cell lung cancer, non-triple-negative breast cancer, triple-negative breast cancer, and metastatic urothelial cancer.\n\nAll participants received SG 10 mg/kg of body weight by IV infusion on Days 1 and 8 of a 21-day treatment cycle.","id":"OG000","title":"SG 10 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants with epithelial cancer that involved any one of the following with available data were analyzed: cervical cancer, colorectal cancer, endometrial cancer, epithelial ovarian cancer, esophageal cancer, gastric adenocarcinoma, glioblastoma multiforme, head \\& neck cancers- squamous cell, hepatocellular carcinoma, hormone-refractory prostate cancer, metastatic, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, renal cell cancer, small-cell lung cancer, non TNBC, TNBC and mUC.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Preinfusion, 30 minutes and 3-4 hours post infusion, then 1 day, 2 days, 3 days, and 7 days later (1 Cycle = 21 days). Infusion duration: 3 hours (± 30 minutes) for 1st infusion; 1-2 hours (± 30 minutes) for subsequent infusions","title":"Pharmacokinetic (PK) Parameter: T1/2 of Total Antibody, SN-38 Glucuronide, Total SN-38, Sacituzumab Govitecan-hziy, and Free SN-38","type":"SECONDARY","unitOfMeasure":"hours"}